ATHX

Athersys Stock Price

1.90
0.13 (7.34%)
Upgrade to Real-Time
Afterhours (Closed)
1.90
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Athersys Inc ATHX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.13 7.34% 1.90 17:00:00
Open Price Low Price High Price Close Price Previous Close
1.83 1.82 1.915 1.90 1.77
Bid Price Ask Price Spread News
1.87 1.92 0.05 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
5,567 1,940,541 $ 1.86 $ 3,615,345 1,921,549 1.12 - 4.42
Last Trade Time Type Quantity Stock Price Currency
16:51:47 81 $ 1.91 USD

Athersys Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 375.63M 197.70M 178.39M $ 5.63M $ - -0.29 -4.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% -95.07k 2.10%

more financials information »

Athersys News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ATHX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.581.9151.531.633,016,0220.3220.25%
1 Month1.801.981.531.712,134,7000.105.56%
3 Months1.992.321.531.851,813,027-0.09-4.52%
6 Months3.003.29591.532.372,751,270-1.10-36.67%
1 Year1.304.421.122.402,796,2760.6046.15%
3 Years2.074.421.002.221,364,514-0.17-8.21%
5 Years1.064.420.972.101,126,3670.8479.25%

Athersys Description

Athersys Inc is a clinical-stage biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is a significant unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.